NCT01695941 2026-03-18
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
141 trialsNCT01861314 2026-03-18
Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04722146 2026-03-13
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT03984097 2026-03-10
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Active not recruiting
NCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
NCT05137054 2026-01-22
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Regeneron Pharmaceuticals
Phase 1 Recruiting
NCT02312102 2026-01-16
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Phase 1 Completed
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT04091126 2025-11-28
DREAMM 9
GlaxoSmithKline
Phase 1 Active not recruiting
NCT00479128 2025-10-28
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT02783625 2025-06-03
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04570631 2025-05-16
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Terminated
NCT00329589 2025-05-02
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
Thomas Jefferson University
Phase 1 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT06900647 2025-04-02
BOCIS
Sun Yat-sen University
Phase 1 Recruiting
NCT04996160 2025-01-24
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
Stanford University
Phase 1 Recruiting
NCT03829020 2024-08-22
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT04956302 2024-06-06
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04912427 2024-02-09
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Washington University School of Medicine
Phase 1 Terminated
NCT02513186 2024-01-29
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation
Sanofi
Phase 1 Completed
NCT02352558 2023-11-14
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02514382 2023-08-14
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Southern California
Phase 1 Completed
NCT05982756 2023-08-09
Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML
Zhongnan Hospital
Phase 1 Unknown
NCT01728259 2023-05-09
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT02484261 2023-03-15
Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
Children's National Research Institute
Phase 1 Terminated
NCT02613598 2021-12-20
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT01038388 2021-11-03
A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma
Emory University
Phase 1 Completed
NCT01965353 2021-09-05
PanRVD
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02481934 2021-08-20
NK-VS-MM
Hospital Universitario 12 de Octubre
Phase 1 Completed
NCT01794507 2021-08-02
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
AbbVie
Phase 1 Completed
NCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT02100657 2020-10-12
Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
PharmaMar
Phase 1 Completed
NCT01248923 2020-09-30
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Array BioPharma
Phase 1 Completed
NCT03515200 2020-09-01
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 1 Terminated
NCT00598169 2020-08-10
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
Phase 1 Completed
NCT01497093 2020-04-07
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT00568880 2020-02-07
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01464112 2020-01-22
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT01445405 2019-12-17
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00023855 2019-12-13
PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors
University of Wisconsin, Madison
Phase 1 Completed
NCT00011778 2019-12-12
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01111188 2019-06-27
Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
Weill Medical College of Cornell University
Phase 1 Terminated
NCT01164709 2019-05-15
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Swiss Cancer Institute
Phase 1 Completed
NCT02497378 2019-03-07
A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT01440582 2019-03-04
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03591744 2018-12-19
Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
City of Hope Medical Center
Phase 1 Withdrawn
NCT00059631 2018-11-15
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00777114 2018-08-13
Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
Weill Medical College of Cornell University
Phase 1 Completed